title: Combined therapeutic hypothermia and barbiturate coma reduces interleukin-6 in the cerebrospinal fluid after aneurysmal subarachnoid hemorrhage.
abstract: Inflammatory response with cytokine release is reported to correlate with clinical outcome after aneurysmal subarachnoid hemorrhage (SAH). In selected cases, hypothermia and barbiturate coma are applied as means for neuroprotection after severe SAH. Hypothermia and high-dose barbiturate are reported to attenuate the inflammatory response. In this pilot study, we assessed the effect of the combined therapy on the inflammatory response. In 15 patients with SAH, daily cerebrospinal fluid (CSF) and plasma samples were collected. Interleukin (IL)-6, tumor necrosis factor alpha (TNF-alpha), IL-1beta, systemic leukocyte, and leukocyte counts in the CSF were quantified. Group 1 represented 7 cases treated with combined therapeutic hypothermia (33 degrees C) and barbiturate coma. Group 2 represented 8 cases without combined therapy. Compared with the systemic levels, all cases showed higher cytokine levels in the CSF. Mean IL-6 level in the CSF was significantly lower in group 1 (P<0.001). The ratio between IL-6 levels in the CSF and plasma, as a parameter for intrathecal synthesis, was significantly lower in group 1 (P=0.014). Mean CSF and systemic levels of TNF-alpha of group 1 were significantly higher compared with group 2 (P=0.009 and P<0.001). The mean systemic IL-1beta level was significantly lower in group 1 (P<0.001), as well as the leukocyte counts, both, systemic and in the CSF (P<0.001 and P=0.032). The present data show a most pronounced decrease of IL-6 levels in the CSF, beside decrease in systemic IL-1beta levels, systemic leukocyte counts, and CSF leukocyte counts in group 1, which would be expected to reflect an attenuation of inflammatory response. The impact and role of TNF-alpha remains unclear.
authors.affiliation: Department of Neurosurgery, University Hospital Zurich, Switzerland. carl.muroi@usz.ch
authors.forename: Carl
authors.initials: C
authors.lastname: Muroi
authors.forename: Karl
authors.initials: K
authors.lastname: Frei
authors.forename: Mohamed
authors.initials: M
authors.lastname: El Beltagy
authors.forename: Evaldas
authors.initials: E
authors.lastname: Cesnulis
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Yonekawa
authors.forename: Emanuela
authors.initials: E
authors.lastname: Keller
mesh_terms: D000328:Adult; D000368:Aged; D001463:Barbiturates / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007036:Hypothermia, Induced; D007249:Inflammation / Q000209:etiology / Q000517:prevention & control*; D053583:Interleukin-1beta / Q000652:urine; D015850:Interleukin-6 / Q000097:blood / Q000134:cerebrospinal fluid*; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D012720:Severity of Illness Index; D013345:Subarachnoid Hemorrhage / Q000134:cerebrospinal fluid / Q000150:complications / Q000188:drug therapy / Q000628:therapy*; D014409:Tumor Necrosis Factor-alpha / Q000097:blood / Q000134:cerebrospinal fluid
chemical_list: D001463:Barbiturates; D053583:Interleukin-1beta; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha